English_Term,Chinese_Term
100% for PRETEXT stage 1,PRETEXT 1期：100%
22% for PRETEXT stage 3,PRETEXT 3期：22%
25% for patients with metastasis,有转移癌的患儿：25%
44% for PRETEXT stage 1,PRETEXT 1期：44%
44% for PRETEXT stage 2,PRETEXT 2期：44%
57% for PRETEXT stage 4,PRETEXT 4期：57%
61% for PRETEXT stage 4,PRETEXT 4期：61%
68% for PRETEXT stage 3,PRETEXT 3期：68%
8% for PRETEXT stage 4,PRETEXT 4期：8%
84% for PRETEXT stage 3,PRETEXT 3期：84%
91% for PRETEXT stage 2,PRETEXT 2期：91%
95% for PRETEXT stage 2,PRETEXT 2期：95%
A clinical trial,参加临床试验
A high mitotic count,核分裂象增多
A poorly differentiated histology,组织学分化较差
A radionuclide bone scan,放射性核素骨显像
A second trial (IBIS-2) is under way,第二项类似试验（IBIS-2）正在进行之中
A thorough physical examination,全面的体格检查
"A total of 8,171 women were enrolled","总计纳入8,171例女性"
AJCC Stage Groupings and TNM Definitions,AJCC分期分组与TNM定义
"AKT1, present in 1% of tumors",AKT1，见于1%的肿瘤
Ablation of Barrett Esophagus With Dysplasia,不典型增生的Barrett食管消融术
About 60%–70% for left colon,对左半结肠约60%-70%
Absent or inconspicuous nucleoli,核仁缺失或不明显
Active and passive cigarette smoking,主动与被动吸烟
Adapted from Altekruse et al,改编自Altekruse et al.
Adapted from Nicol et al,引用Nicol et al.
Adapted from Russo et al,数据源自Russo et al.
Added Aflibercept as a new subsection,添加“阿柏西普​”章节
Added Pertuzumab as a new subsection,增添内容：帕妥珠单抗章节
Added Third-line chemotherapy as a new subsection,添加“三线化疗”章节
Addition of radiation therapy,添加放疗
Adenocarcinoma (40% of lung cancers),腺癌（40%的肺癌）
Adenocarcinoma (most colon cancers),腺癌（多数结肠癌）
Adenocarcinoma with mixed subtypes,腺癌混合亚型
Adenoid cystic carcinoma,腺样囊性癌
Adherence to or invasion of adjacent organs,粘连或浸润毗邻器官
Adjuvant Systemic Therapy,辅助全身治疗
Adjuvant chemoradiation therapy,辅助放化疗
Adjuvant chemotherapy following chemoradiation therapy and surgery,放化疗和手术后的辅助化疗
Adjuvant radiation and chemotherapy,辅助放疗与化疗
Adult Hodgkin Lymphoma Treatment,成人霍奇金淋巴瘤的治疗
Adult Primary Liver Cancer (PDQ®): Treatment,成人原发性肝癌（PDQ®）：治疗
Adult Soft Tissue Sarcoma Treatment,成人软组织肉瘤的治疗
Age at Diagnosis,诊断年龄
Age at entry: 39 to 41 years,入组年龄：39到41岁
Age at entry: 39 to 59 years,入组年龄：39到59岁
Age at entry: 40 to 49 years,入组年龄：40到49岁
Age at entry: 40 to 64 years,入组年龄：40到64岁
Age at entry: 40 to 74 years,入组年龄：40到74岁
Age at entry: 45 to 64 years,入组年龄：45到64岁
Age at entry: 45 to 69 years,入组年龄：45到69岁
Age at entry: 50 to 59 years,入组年龄：50到59岁
Age versus comorbidity,年龄与合并症
Alpha-fetoprotein (AFP) levels,甲胎蛋白（AFP）水平
Alternative drug doses and schedules,变换药物剂量与方案
An American series has confirmed these results,另一项美国的系列临床研究亦证实了这一结果
Analysis: Both evaluation and follow-up methods,分析方法：联合评估和随访分析法
Anaplastic lymphoma kinase receptor (ALK),间变性淋巴瘤激酶受体（ALK）
"Any T, Any N, M1a",任何T，任何N，M1a
"Any T, Any N, M1b",任何T，任何N，M1b
Any stage may have involvement of:,各分期均可能有下列结构受累：
Appendix of Randomized Controlled Trials,附录：随机对照试验
Arm A: fluoropyrimidine/oxaliplatin,A组：氟嘧啶/奥沙利铂
Arm B: fluoropyrimidine/oxaliplatin/cetuximab,B组：氟嘧啶/奥沙利铂/西妥昔单抗
Arm C: intermittent fluoropyrimidine/oxaliplatin,C组：间歇性氟嘧啶/奥沙利铂
Aromatase inhibition or inactivation,芳香化酶抑制或灭活
Aromatase inhibitors or inactivators: Benefits,芳香化酶抑制剂或灭活剂：获益
Aromatase inhibitors or inactivators: Harms,芳香化酶抑制剂或灭活剂：危害
Aspirin and nonsteroidal anti-inflammatory drug use,阿司匹林和非甾体类抗炎药（NSAID）
Aspirin and nonsteroidal anti-inflammatory drugs,阿司匹林和非甾体类抗炎药
Assessment of Performance and Accuracy,有效性及准确度的评估
Assessment of outcome was not blinded,结果评估未设盲
Attendance in this study was 65%,该研究出勤率为65%
Attenuated familial adenomatous polyposis (AFAP): APC gene,轻表型家族性腺瘤性息肉病（AFAP）：APC基因
Avoidance of tobacco and alcohol,远离吸烟与饮酒
Axillary lymph node surgery,腋窝淋巴结手术
BCSC Web site,BCSC 网站
BRCA1 and BRCA1 mutations,BRCA1和BRCA2基因突变
Barcelona Clinic Liver Cancer (BCLC) Staging System,巴塞罗那临床肝癌（BCLC）分期系统
Barium-meal gastric photofluorography,上消化道钡餐造影
Beckwith-Wiedemann syndrome and hemihyperplasia,Beckwith-Wiiedemann综合征与偏侧发育过度
Benefit of Mammography,乳腺X线摄影的益处
Benefit of chemotherapy,化疗获益
Beta-carotene in nonsmokers,非吸烟者补充β-胡萝卜素
Beta-carotene supplementation in current smokers,当前吸烟者补充β-胡萝卜素
Beta-carotene supplementation in nonsmokers,非吸烟者补充β-胡萝卜素
Beta-carotene supplementation in smokers,吸烟者补充β-胡萝卜素
Biliary Tract Rhabdomyosarcoma,胆道横纹肌肉瘤
Bladder control symptoms,膀胱控制症状
"Body fluids, e.g., blood, semen",体液，例如血液、精液
Both T4a and T4b,同时满足T4a和T4b
Breast Cancer (PDQ®): Prevention,乳腺癌（PDQ®）：预防
Breast Cancer (PDQ®): Screening,乳腺癌（PDQ®）：筛查​
Breast Cancer (PDQ®): Treatment,乳腺癌（PDQ®）：治疗
Breast Cancer Diagnosis and Pathology,乳腺癌的诊断和病理学
Breast Cancer Screening Concepts,乳腺癌的筛查概念
Breast Cancer Screening Modalities—Beyond Mammography,乳腺癌筛查方法——除乳腺X线摄影之外的其他方法
Breast Cancer Screening Modalities—Mammography,乳腺癌筛查方法——乳腺X线摄影
Breast Cancer Surveillance Consortium,乳腺癌监管联合会
Breast Cancer Surveillance Consortium (BCSC) Web site,乳腺癌监管联合会（BSCS）网站
Breast Cancer Treatment and Pregnancy,乳腺癌治疗与妊娠
Breast cancer incidence and mortality,​乳腺癌的发病率和死亡率
Breast-conserving surgery without radiation therapy,​保乳手术，不行放疗
Burkitt-like/atypical Burkitt lymphoma,类Burkitt、不典型Burkitt淋巴瘤
CA: cyclophosphamide and doxorubicin,CA：环磷酰胺，阿霉素
CAF: cyclophosphamide plus doxorubicin plus fluorouracil,CAF：环磷酰胺、阿霉素、氟尿嘧啶
"CAF: cyclophosphamide, doxorubicin, 5-fluorouracil",CAF：环磷酰胺，阿霉素，5-氟尿嘧啶
CMF: cyclophosphamide plus methotrexate plus fluorouracil,CMF：环磷酰胺、甲氨蝶呤、氟尿嘧啶
"CMF: cyclophosphamide, methotrexate, 5-fluorouracil",CMF：环磷酰胺，甲胺蝶呤，5-氟尿嘧啶
Capecitabine and ixabepilone,卡培他滨联合伊沙匹隆
Capecitabine plus weekly oxaliplatin with radiation therapy,卡培他滨联合每周一次奥沙利铂和放疗
Capecitabine with radiation therapy,卡培他滨联合放疗
"Carcinoma, NOS (not otherwise specified)",​癌，NOS（如无特殊说明）
Carcinomas of salivary gland type,涎腺癌类型
"Carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements",多形性癌、肉瘤样癌或含肉瘤成分的癌
Carcinomas with spindle and/or giant cells,梭形和（或）巨细胞癌
Cardiac mortality decreased accordingly,心脏相关死亡率随之下降
Cardiac toxic effects with adjuvant trastuzumab,曲妥珠单抗辅助治疗的心脏毒性反应
"Case-control studies, RCTs in progress",病例对照研究，正在进行中的RCT
Cause of death attribution: Cancer Registry Data,死亡原因分析：癌症登记数据
Celecoxib 200 mg/qd vs 400 mg bid,塞来昔布200 mg/qd与400 mg bid
Cellular Classification and Pathology of Rectal Cancer,直肠癌的细胞学分类和病理
Cellular Classification of Adult Primary Liver Cancer,成人原发性肝癌的细胞学分类
Cellular Classification of Breast Cancer,乳腺癌的细胞学分型
Cellular Classification of Colon Cancer,结肠癌的细胞学分类
Cellular Classification of Esophageal Cancer,食管癌的细胞学分类
Cellular Classification of Gastric Cancer,胃癌的细胞学分类
Cellular Classification of NSCLC,NSCLC的细胞学分类
Cellular Classification of Small Cell Lung Cancer,小细胞肺癌的细胞分类
Cetuximab/Panitumumab and Second-Line Chemotherapy,西妥昔单抗/帕尼单抗与二线化疗
Change in appetite,食欲改变
Change in bowel habits,​排便习惯改变
Characteristics of Cancers Detected by Screening Mammography,经乳腺X线摄影筛查检出肿瘤的特性
Chemoprevention sporadic adenoma,化学预防散发性腺瘤
Chemoradiation with subsequent surgery,术前放化疗联合手术
Chemotherapy alone for local control,单用化疗以进行局部控制
Chemotherapy and metastatic disease,化疗与肿瘤转移
Chemotherapy and radiation therapy,化疗联合放疗
Chemotherapy and tamoxifen risks,化疗联合他莫昔芬的风险
Chemotherapy and targeted therapy,化疗和靶向治疗
Chemotherapy combined with radiation therapy and/or surgery,化疗联合放疗和（或）手术
Chemotherapy followed by reassessment of surgical resectability,化疗后应重新评估肿瘤的可切除性
Chemotherapy followed by surgery (for selected patients),化疗后手术（适用于某些患者）
Chemotherapy or kinase inhibitors alone,单独化疗或激酶抑制剂
Chemotherapy regimens after 2000,2000年后使用的化疗方案
Chemotherapy regimens prior to 2000,早于2000年使用的化疗方案
Chemotherapy-related toxicities were greater with prolonged chemotherapy,延长化疗后化疗相关毒性反应发生率升高
Childhood Liver Cancer (PDQ®): Treatment,儿童肝癌（PDQ®）：治疗
Childhood Rhabdomyosarcoma Treatment,儿童横纹肌肉瘤的治疗
Chronic atrophic gastritis,慢性萎缩性胃炎
Cigarette smoking is the primary risk factor,吸烟是主要的危险因素
"Cigarette, pipe, or cigar smoking",香烟、烟斗烟或雪茄烟
Cirrhosis and other factors,肝硬化与其他因素
Cisplatin + irinotecan,顺铂+伊立替康
Clear cell adenocarcinoma,透明细胞腺癌
Clear cell carcinoma,透明细胞癌
Clinical Breast Examination,​临床乳腺检查
Clinical Evaluation and Staging,临床评估与分期
Clinical Presentation and Symptoms,临床表现与症状
Clinical considerations for high risk groups,对高危人群的临床建议
Clinical trials evaluating new drugs,新药评估临床试验
Clinical trials evaluating single-agent or combination chemotherapy,评估单药化疗或联合化疗的临床试验
Close or microscopically positive resection margins,临近切缘或切缘镜下阳性
Colon Cancer (PDQ®): Treatment,结肠癌（PDQ®）：治疗​
Colorectal Cancer (PDQ®): Prevention,结直肠癌（PDQ®）：预防​
Colorectal Cancer (PDQ®): Screening,结直肠癌（PDQ®）：筛查​
Combination chemotherapy alone,单独联合化疗
Combination chemotherapy and radiation therapy,联合化疗与放疗
Combination chemotherapy with bevacizumab or cetuximab,化疗联合贝伐单抗或西妥昔单抗
Combination hormone therapy,联合激素治疗
Combination of CT imaging and FDG-PET scanning,CT联合FDG-PET
Combination of FOBT and Flexible Sigmoidoscopy,FOBT联合软式乙状结肠镜
Combined modality approaches,综合治疗
Combining local treatment (surgery),联合局部治疗（手术）
Comments: Randomization process was flawed,评论：随机分组过程存在瑕疵
Compliance: 61% screened,依从性：61%的受试者完成了筛查
Compliance: 82% screened,依从性：82%的受试者完成了筛查
Compliance: 89% participation,依从性：参与度89%
Compliance: 89% screened,依从性：89%的受试者完成了筛查
Computed Tomographic (CT) Colonography,计算机断层扫描（CT）结肠成像
Concurrent chemotherapy with radiation therapy and surgery,同步放化疗与手术
Concurrent versus sequential chemoradiation therapy,同步与序贯放化疗
Consistency : Fair,​一致性： 一般
Consistency : Good; multiple studies,一致性：佳，多项研究
Consistency : Inadequate evidence,一致性：证据不足
Consistency : Large study,一致性：大型研究
Consistency : Multiple studies,一致性： 多项研究
Consistency : Poor in prospective studies,一致性：前瞻性研究中一致性较差
Consistency : Single study,一致性：单项研究
Consistency and External Validity : Poor,​一致性和外部效度：较差
Consistency of reports: Good,报告的一致性：佳
Consistency of reports: Not applicable,报告的一致性：不适用
Consistency of reports: Variable,报告的一致性：多样
"Consistency: Multiple studies, large number of participants",一致性：多项研究，参与者人数较多
Consistency: Small number of studies,一致性：研究数量少
Contamination: 16.9% of the CBE only group,干扰：单独CBE筛查组16.9%出现了干扰
Contamination: 26.4% in usual care group,干扰：常规护理组26.4%出现了干扰
Continuing only single-agent chemotherapy,继续单药化疗
Continuing the initial combination chemotherapy regimen,继续初始联合化疗方案
Control: Annual CBE,对照组：每年进行一次CBE
Control: MMG at year 5,对照组：第5年进行一次MMG
Control: Usual care,对照组：常规护理
Cost effectiveness of FDG-PET scanning,FDG-PET扫描的成本效益分析
Cowden syndrome: PTEN gene,​Cowden综合征：PTEN基因
Current Age (in Years),目前年龄（岁）
Cushing syndrome from secretion of adrenocorticotropic hormone,促肾上腺皮质激素分泌过量引起库欣综合征
Cycle Number and Duration (d),疗程数与持续时间（天）
Cyclophosphamide + doxorubicin + etoposide,环磷酰胺+阿霉素+依托泊苷
Cyclophosphamide + doxorubicin + vincristine,环磷酰胺+阿霉素+长春新碱
Cyclophosphamide + etoposide + vincristine,环磷酰胺+依托泊苷+长春新碱
Cytotoxic combination chemotherapy (first line),细胞毒性药物联合化疗（一线）
Cytotrophoblasts and syncytiotrophoblasts are both present,婴儿肝绒毛膜癌中可见细胞滋养层与合体滋养层细胞
DCIS is most often diagnosed by mammography,DCIS最常通过乳腺X线摄影诊断
"Deaths: 50,830 (colon and rectal cancers combined)","死亡病例数：50,830（合并结肠癌与直肠癌）"
Definition of prevention,预防的定义
Definitions of TNM,TNM分期的定义
Delayed surgical resection (chemotherapy followed by surgery),延期手术（术前化疗）
Dense breast tissue,乳腺组织致密
Description of Evidence,证据描述
Description of the Evidence,​证据描述
Detection of DNA Mutations in the Stool,粪便DNA突变检测
Developing more effective systemic therapy,开发更有效的全身治疗
Diagnostics and Survival,诊断和生存
Diet and vitamins,饮食与维生素
Diet low in fruits and vegetables,新鲜果蔬摄入减少
Dietary fat and meat intake,摄取膳食脂肪与肉类
"Dietary fiber, vegetables, and fruit",膳食纤维与蔬果
Diffuse large B-cell lymphoma,弥漫性大B细胞淋巴瘤
Digital Rectal Exam,直肠指检
Digital Rectal Examination,直肠指检
Docetaxel and capecitabine,多西他赛联合卡培他滨
Docetaxel and cyclophosphamide,多西他赛联合环磷酰胺
Docetaxel and doxorubicin,多西他赛联合阿霉素
Docetaxel plus pertuzumab,多西他赛联合帕妥珠单抗
Docetaxel plus trastuzumab,多西他赛联合曲妥珠单抗
Docetaxel plus trastuzumab and pertuzumab,多西他赛、曲妥珠单抗联合帕妥珠单抗
Dominant Geographical Area,主要地理区域
Dominant Geographical Areas,主要地区
Dose and timing,剂量与时间
"Dose-intensity, dose-density, and high-dose chemotherapy",剂量强度、剂量密度与大剂量化疗
Doxorubicin and paclitaxel,阿霉素联合紫杉醇
Ductal Carcinoma In Situ,​导管内原位癌
EGFR tyrosine kinase inhibitors (first line),EGFR酪氨酸激酶抑制剂（一线）
EML4-ALK inhibitors in patients with EML-ALK translocations,EML-ALK易位患者使用EML4-ALK抑制剂
ER and PR status testing,ER和PR表达情况检测
ER or PR status,ER或PR状态
ER–positive tumors were reduced by 48%,ER阳性乳腺癌发病率降低48%
Early eradication of micrometastases,早期根治微转移灶
Ecologic and descriptive studies,生态学与描述性研究
Effectiveness of Population-Based Screening Programs,基于人群的筛查项目的有效性
Efficacy of Screening and Surveillance Programs,筛查与监测项目的有效性
Eliminating secondhand smoke,消除二手烟
Endocavitary radiation therapy,盆腔内放疗
Endoscopic-placed stents to provide palliation of dysphagia,内镜下放置支架以缓解吞咽困难
"Enterochromaffin (EC)-cell, serotonin-producing neoplasm",分泌血清素的肠嗜铬细胞（EC）瘤
Epidermoid or squamous cell carcinoma,表皮样癌或鳞状细胞癌
Esophageal Cancer (PDQ®): Prevention,食管癌（PDQ®）：预防
Esophageal Cancer (PDQ®): Screening,食管癌（PDQ®）：筛查
Esophageal Cancer (PDQ®): Treatment,食管癌（PDQ®）：治疗​
Esophageal Cancer Prevention,食管癌的预防
Esophageal Cancer Screening,食管癌筛查
Esophageal Cancer Treatment,食管癌的治疗
Estrogen-only use among women with a hysterectomy,子宫切除术后女性应用雌激素
Etiology and pathogenesis of breast cancer,乳腺癌的病因和病理机制
Etiology and pathogenesis of colorectal cancer,结直肠癌的病因和发病机制
Etoposide + carboplatin,依托泊苷+卡铂
Etoposide + cisplatin,依托泊苷+顺铂
Evaluation of Breast Symptoms,​乳房症状评估
Evaluation of brain metastasis,脑转移的评估
Evaluation of mediastinal lymph node metastasis,纵隔淋巴结转移的评估
Evidence (5-FU alone and 5-FU-semustine):,证据（单独使用5-FU或5-FU-司莫司汀）：
Evidence (CT scan):,证据（CT扫描）：
Evidence (CT/FDG-PET scan):,证据（CT/FDG-PET）：
Evidence (EGFR tyrosine kinase inhibitors):,证据（EGFR酪氨酸激酶抑制剂）：
Evidence (FDG-PET scan):,证据（FDG-PET扫描）：
Evidence (adjuvant chemoradiation therapy):,证据（辅助放化疗）：
Evidence (adjuvant chemotherapy for stage I NSCLC):,证据（对I期NSCLC的辅助化疗）：
Evidence (adjuvant chemotherapy for stage IB NSCLC):,证据（对IB期NSCLC的辅助化疗）：
Evidence (age vs. comorbidity):,证据（年龄与合并症）：
Evidence (chemoradiation therapy):,证据（放化疗）：
Evidence (chemotherapy and targeted therapy):,证据（化疗与靶向治疗）：
Evidence (combination chemotherapy with bevacizumab or cetuximab):,证据（化疗联合贝伐单抗或西妥昔单抗）：
Evidence (combination chemotherapy):,证据（联合化疗）：
Evidence (combined modality treatment):,证据（综合治疗）：
Evidence (concurrent vs. sequential chemoradiation therapy):,证据（同步与序贯放化疗）：
Evidence (drug and dose schedule):,证据（药物及剂量方案）：
Evidence (endobronchial therapies):,证据（经支气管镜治疗）：
Evidence (laparoscopic techniques):,证据（腹腔镜手术）：
Evidence (maintenance erlotinib following platinum-based doublet chemotherapy):,证据（含铂类双药化疗后厄洛替尼维持治疗）：
Evidence (maintenance therapy following first-line chemotherapy):,证据（一线化疗后的维持治疗）：
Evidence (neoadjuvant chemotherapy):,证据（新辅助化疗）：
Evidence (nodal status):,证据（淋巴结情况）：
Evidence (other combination chemotherapy regimens):,证据（其他联合化疗方案）：
Evidence (radiation therapy for palliative treatment):,证据（放疗作为姑息疗法）：
Evidence (radiation therapy):,证据（放疗）：
Evidence (radical surgery):,证据（根治性手术）：
Evidence (role of PCI):,证据（PCI的作用）：
Evidence (role of surgery):,证据（手术的作用）：
Evidence (standard regimens):,证据（标准方案）：
Evidence about colorectal cancer mortality reduction,关于结直肠癌死亡率降低的证据
Evidence about colorectal cancer reduction,减少结直肠癌的证据
Evidence about lesion detection rate,病变检出率证据
Evidence of Benefit,有益的证据
Evidence of Benefit Associated With Screening,筛查相关获益证据
Evidence of Harm,危害证据
Evidence of Harm Associated With Screening,筛查伤害证据
Evidence of Harms,危害证据
Evidence of No Benefit Associated With Screening,无筛查获益的证据
Evidence of no benefit associated with screening,筛查无获益证据
Examination of the tumor,肿瘤检查
Excessive alcohol use,过度饮酒
"Exclusions: Few, balanced between groups",排除：很少，各组间保持平衡
Exclusions: Inconsistently reported,排除：各项报告排除例数不一致
Exposure to secondhand smoke,二手烟的暴露
Extensive-Stage Small Cell Lung Cancer Treatment,广泛期小细胞肺癌的治疗
External Validity : Poor,可推广性： 差
"External Validity: Good, data from national databases",外部效度：佳，数据来自美国国家数据库
External Validity: N/A,外部效度：不适用
External Validity: Poor,可推广度：较差
External audit: No,外部审核：无
External audit: None,外部审核：无
External audit: Yes,外部稽查：有
Extracapsular tumor spread,包膜外肿瘤侵犯
Extracolonic abnormalities are common in CT colonography,​CT结肠成像中常可见结肠外异常病变
Factors influencing treatment,影响治疗的因素
Factors influencing treatment with chemotherapy,影响化疗的因素
Factors of Unproven or Disproven Association,相关性未经证实或已经证伪的因素
Factors of uncertain association with risk,与肺癌风险关系尚不明确的因素
False positive exams,检查假阳性
False-Positives Leading to Possible Additional Interventions,​假阳性导致额外干预
Familial adenomatous polyposis,家族性腺瘤性息肉病
Familial adenomatous polyposis (FAP): APC gene,​家族性腺瘤性息肉病（FAP）：APC基因
Family history of gastric cancer,胃癌家族史
Fecal Occult Blood Test,便潜血检查
Fecal Occult Blood Test (FOBT),便潜血检查（FOBT）
Fecal Occult Blood Testing (FOBT),便潜血检查（FOBT）
Final results of this trial are pending,该试验最终结果尚未公布
"Finely granular ""salt and pepper"" chromatin",染色质呈细颗粒状“盐和胡椒”样
First-line multiagent chemotherapy,一线多药化疗
Fluorodeoxyglucose-positron emission tomography (FDG-PET) scanning,氟脱氧葡萄糖正电子发射断层扫描（FDG-PET）
Follow-up continued for up to 16 years,随访共达16年
Follow-up duration: 10 years,随访时间：10年
Follow-up duration: 10.7 years,随访时间：10.7年
Follow-up duration: 12 to14 years,随访时间：12到14年
Follow-up duration: 12 years,随访时间：12年
Follow-up duration: 13 years,随访时间：13年
Follow-up duration: 18 years,随访时间：18年
Follow-up duration: 8 years,随访时间：8年
Follow-up ranged from 6 to 13 years,随访时间为6-13年
For palliative treatment,作为姑息治疗
For treatment of locally advanced unresectable tumor,作为局部晚期不可切除肿瘤的治疗
Frequent nuclear molding,常见核铸型
Frequently; jaundice is a common presenting symptom,多见，黄疸为常见症状
Full recovery (usually),完全治愈（常见结局）
Further follow-up is anticipated,尚需进一步随访
Gastric Cancer (PDQ®): Treatment,胃癌（PDQ®）：治疗
Gastric adenomatous polyps,胃腺瘤性息肉
Gastroesophageal reflux/Barrett esophagus,胃食管返流症/Barrett食管
Gastrointestinal Stromal Tumors Treatment,胃肠道间质肿瘤治疗
Gastrointestinal stromal tumor,胃肠道间质瘤
General Information About Adult Primary Liver Cancer,成人原发性肝癌的基本信息
General Information About Breast Cancer,乳腺癌的基本信息
General Information About Colon Cancer,结肠癌的基本信息
General Information About Esophageal Cancer,​食管癌的基本信息
General Information About Gastric Cancer,胃癌基本信息
General Information About Male Breast Cancer,男性乳腺癌的基本信息
General Information About Rectal Cancer,​直肠癌的基本信息
General Information About Small Cell Lung Cancer,小细胞肺癌（NSCLC）的基本信息
Generalizability to other populations is uncertain,结果对其他人群的适用性并不确定
Genetic Characteristics and Risk Factors,遗传学特征和危险因素
Genetic risk factors,​遗传性危险因素
Genetics of Breast and Ovarian Cancer,乳腺癌与卵巢癌的遗传学
Genetics of Colorectal Cancer,结直肠癌的遗传学
German Rectal Cancer Study Group,德国直肠癌研究组
Giant cell carcinoma,巨细胞癌
Glycogen storage diseases I–IV,I-IV型糖原储积症
H. pylori infection eradication,根除幽门螺杆菌感染
"HER2, present in 2% of tumors",HER2，见于2%的肿瘤
HER2/neu receptor status testing,HER2/neu表达情况检测
HGD = high-grade dysplasia,HGD = 重度不典型增生
Harms of Screening Mammography,乳腺X线摄影筛查的危害
Helicobacter pylori gastric infection,胃幽门螺旋杆菌感染
Helicobacter pylori infection and gastric atrophy,幽门螺杆菌与胃粘膜萎缩
Hepatic Virus Types,肝炎病毒类型
Hepatitis B Vaccine to Prevent Hepatocellular Cancer,乙肝疫苗对肝细胞癌的预防
Hepatitis B and C,乙型肝炎与丙型肝炎
Hepatitis B and hepatitis C infection,乙肝与丙肝病毒感染
Hepatitis B virus,乙肝病毒
Hepatitis C virus,丙肝病毒
Hepatitis D causes swelling of the liver,丁型肝炎引起肝脏肿胀
Hepatoblastoma and Hepatocellular Carcinoma,肝母细胞瘤与肝细胞癌
Hepatoblastoma prognosis by postsurgical stage,术后分期与肝母细胞瘤的预后
Hepatoblastoma rarely occurs in adults,肝母细胞瘤在成人中罕见
Hereditary mixed polyposis syndrome,遗传性混合性息肉病综合征
High risk Any patient with metastases,高危任何有转移的患者
High-grade glandular intraepithelial neoplasia,高级别腺上皮内瘤变
Histologic classification is as follows:,组织学分类如下：
Hormonal therapies may be used sequentially,内分泌治疗可以为序贯治疗
Hormone Replacement Therapy,激素替代治疗
Hormone therapy (estrogen plus progestin),激素治疗（雌激素联合孕激素）
Human epidermal growth factor receptor 2 (HER2),人表皮生长因子受体2（HER2）
Human immunodeficiency virus (HIV) infection,人类免疫缺陷病毒（HIV）感染
Hyperplastic polyposis syndrome: BRAF and KRAS2 genes,​增生性息肉综合征：BRAF和KRAS2基因
IASLC-AJCC TNM Staging System,IASLC-AJCC TNM分期系统
Ifosfamide + cisplatin + etoposide,异环磷酰胺+顺铂+依托泊苷
Inadequate lymph node sampling,淋巴结清扫数目不足
Inappropriate antidiuretic hormone secretion,抗利尿激素分泌失调
"Incidence (per 100,000 population)",发病率（每10万人口）
Incidence and Mortality,​发病率与死亡率
"Incidence of Outcomes Per 1,000 Women",每一千女性的结局发生率
Incidence of Symptoms (0–4 scale),症状发生率（0-4分量表）
"Incidence, Mortality, and Risk Factors",发病率、死亡率与危险因素
Individuals With Little to Gain from Screening,筛查获益很小的人群
Infantile Choriocarcinoma of the Liver,婴儿肝绒毛膜癌
Infected drinking water,被感染的饮用水
Initial Surgical Management,初始手术治疗
"Initially, hormonal therapy is recommended",内分泌治疗开始作为推荐治疗方法
Intention-to-treat analysis was not used,未使用意向治疗分析
Intermediate-grade atypical carcinoid,中等分级不典型类癌
Internal Validity : Fair,可信度：一般
Internal Validity : Good,​内部效度： 佳
Internal Validity and Consistency : Fair,内部效度和一致性： 一般
Internal Validity: Not applicable (N/A),内部效度：不适用
Intervention: Annual two-view MMG and CBE,试验组：每年进行双视图MMG和CBE
Intraductal cancer has been described as well,导管内癌也较为常见
Intraluminal brachytherapy to provide palliation of dysphagia,腔内近距离放射治疗以缓解吞咽困难
Intratumoral injection of alcohol,肿瘤内注射无水乙醇
"Introducing a new agent as ""maintenance.""",使用新药作为“维持治疗”
Invasive breast cancer,浸润性乳腺癌
Involvement of multiple nodal stations,多站淋巴结受累
Involvement of pleura,胸膜受累情况
Involvement of the visceral peritoneum,肿瘤累及脏层腹膜
Ionizing radiation exposure,电离辐射
It is a sexually transmitted disease,乙型肝炎属于性传播疾病
Kirsten rat sarcoma viral oncogene (KRAS),Kirsten鼠肉瘤病毒致癌基因（KRAS）
Knowledge of histologic type,病理类型
Lambert-Eaton myasthenic syndrome,Lambert-Eaton肌无力综合征
Lapatinib plus capecitabine,拉帕替尼联合卡培他滨
Lapatinib plus paclitaxel,拉帕替尼联合紫杉醇
Lapatinib plus trastuzumab,拉帕替尼联合曲妥珠单抗
Large cell carcinoma,大细胞癌
Large cell carcinoma (10% of lung cancers),大细胞癌（10%的肺癌）
Large cell carcinoma with rhabdoid phenotype,横纹肌样表型的大细胞癌
Large cell neuroendocrine carcinoma (LCNEC),大细胞神经内分泌癌（LCNEC）
Large tumor size (>3 cm),肿瘤较大（>3cm）
Large tumors (T2 lesions),​肿瘤较大（T2期病变）
Late Effects of Treatment for Childhood Cancer,儿童肿瘤治疗的后期效果
Late toxic effects of radiation,放疗的迟发毒性作用
Length of treatment,治疗持续时间
Levamisole alone did not confer these benefits,单独使用左旋咪唑进行化疗无此获益
Level of evidence: 1iDii,证据等级：1iDii
Level of evidence: 1iiA,证据等级：1iiA
Levels of Evidence,​证据等级
Lifetime Risk of a Breast Cancer Diagnosis,乳腺癌诊断的终生风险
Likely Etiology of HCC,肝细胞癌的可能病因
Limitations of evidence (surgery):,证据局限性（手术）：
Limited Role for Radiation Therapy,放疗的有限作用
Limited-Stage Small Cell Lung Cancer Treatment,局限期小细胞肺癌的治疗
Linked to Swedish Cause of Death Registry,研究数据连接瑞典死亡原因登记处
Little or no association with cancer,与肝癌相关性小或不相关
Liver (Hepatocellular) Cancer (PDQ®): Prevention,肝（肝细胞）癌（PDQ®）：预防
Liver (Hepatocellular) Cancer (PDQ®): Screening,肝癌（肝细胞癌）（PDQ®）：筛查
Liver (Hepatocellular) Cancer Prevention,肝（肝细胞）癌的预防
Liver (Hepatocellular) Cancer Screening,肝（细胞）癌的筛查
Lobular Carcinoma In Situ,小叶原位癌
Local excision or simple polypectomy,局部切除术或单纯息肉切除术
Local radiation therapy,局部放疗
Locally (T3–T4) and/or regionally (N2–N3) advanced disease,局部（T3-T4）和（或）区域（N2-N3）晚期肿瘤
Locally Recurrent Disease,局部复发
Locally Recurrent Rectal Cancer,局部复发性直肠癌
Low Risk (Has All Listed Factors),低危（满足下列所有条件）
Low-grade glandular intraepithelial neoplasia,低级别腺上皮内瘤变
Low-grade typical carcinoid,低分级典型类癌
Lung Cancer (PDQ®): Prevention,肺癌（PDQ®）：预防
Lung Cancer (PDQ®): Screening,肺癌（PDQ®）：筛查​
Lung Cancer Screening,肺癌的筛查
Lung cancer in never smokers,从不吸烟者的肺癌
M0 = No distant metastasis,M0=无远处转移
M1 (contralateral lung),M1（对侧肺）
M1 (ipsilateral lung),M1（同侧肺）
M1 = Distant metastasis,M1=有远处转移
M1b = Distant metastasis (in extrathoracic organs),M1b=远处转移（胸腔外器官）
M1b designates distant metastasis,M1b指有远处转移
MAC is the modified Astler-Coller classification,MAC系统为改良Astler-Coller分期标准
MAPK kinase 1 (MAP2K1 or MEK1),MAPK激酶1（MAP2K1或MEK1）
MET oncogene encodes hepatocyte growth factor receptor,MET致癌基因编码肝细胞生长因子受体
Magnetic Resonance Imaging,​磁共振成像
Magnitude of Effect : No effect,​效应强度： 无效
"Magnitude of Effect: Increased risk, small magnitude",效应强度：风险增加，程度小
Magnitude of Effects,效应强度
Magnitude of Effects on Surrogate Endpoints,对间接终点的效应强度
Maintenance therapy following first-line chemotherapy,一线化疗后的维持治疗
Major inheritance susceptibility,主要遗传易感性
Male Breast Cancer (PDQ®): Treatment,男性乳腺癌（PDQ®）：治疗​​
Male breast cancer is rare,男性乳腺癌十分罕见
Mammography Description and Background,乳腺X线摄影的描述及背景
Mammography and CAD,乳腺X线摄影及CAD
"Mammography screening rates, however, were generally low",但研究中，使用乳腺X线摄影进行筛查的比例较低
Mammography—Variables Associated with Accuracy,乳腺X线摄影——影响准确性的变量
Mantle cell lymphoma,套细胞淋巴瘤
Many agents are active in esophageal cancer,多种药物可有效治疗食管癌
Median age 10.5 y,中位数：10.5岁
Median age 3.4 y,中位数：3.4岁
Medullary carcinomas may be similarly missed,髓样癌出于同样的原因也可能会被漏诊
Menetrier disease (giant hypertrophic gastritis),梅内特里耶病（肥厚性胃炎）
Metaplastic columnar epithelium,柱状上皮化生
Metaplastic intestinal epithelium with typical goblet cells,有典型杯状细胞的肠上皮化生
Metastases in 1–3 axillary lymph nodes,1-3枚腋窝淋巴结转移
Metastases in 1–3 regional lymph nodes,1-3枚区域淋巴结转移
Metastases in 2–3 regional lymph nodes,2-3枚区域淋巴结转移
Metastases in 4–6 regional lymph nodes,4-6枚区域淋巴结转移
Metastases in 4–9 axillary lymph nodes,4–9枚腋窝淋巴结转移
Metastases in 7–15 regional lymph nodes,7-15个区域淋巴结转移
Metastases in >1 organ/site or the peritoneum,远处转移分布于一个以上的器官/部位或腹膜转移
Metastases in ipsilateral infraclavicular lymph node(s),同侧锁骨下淋巴结转移
Metastases in ipsilateral supraclavicular lymph node(s),同侧锁骨上淋巴结转移
Metastases in ipsilateral supraclavicular lymph nodes,同侧锁骨上淋巴结转移
Metastases in ≥10 axillary lymph nodes,10枚及以上腋窝淋巴结转移
Metastases in ≥16 regional lymph nodes,≥16个区域淋巴结转移
Metastases in ≥4 regional lymph nodes,≥4枚区域淋巴结转移
Metastases in ≥7 regional lymph nodes,≥7枚区域淋巴结转移
Metastasis in 1 regional lymph node,1枚区域淋巴结转移
Metastatic Rectal Cancer,转移性直肠癌
Microscopic residual disease after resection,切除术后显微镜下残留病灶
Mode of Transmission,传播途径
Multiple tumors >5 cm,多发性肿瘤，大小超过5cm
N/A = not available,N/A=不可用
N0 = No regional lymph node metastasis,N0=无区域淋巴结转移
NSCLC is a heterogeneous aggregate of histologies,NSCLC具有多种不同的组织学类型
Naproxen seemed least harmful,相对而言，萘普生的风险最低
Natural History and Prognostic Factors,自然病程与预后因素
"Natural History, Incidence, and Mortality",自然病程、发病率及死亡率
Nausea and Vomiting,恶心与呕吐
Nd:YAG endoluminal tumor destruction or electrocoagulation,Nd：YAG激光腔内肿瘤毁坏术或电凝术
Nearly 92% of tests were rehydrated,近92%的检查为再水化检查
Nested case-control study all users,​巢式病例对照研究所有用户
Neuroendocrine tumors include the following:,神经内分泌肿瘤包括：
"New cases: 102,480 (colon cancer only)","新发病例数：102,480例（仅结肠癌）"
"New cases: 17,990","新发病例数：17,990例"
"New cases: 2,240","新发病例：2,240例"
"New cases: 21,600","新发病例数：21,600例"
"New cases: 224,210","新发病例数：224,210例"
"New cases: 235,030","​新发病例数：235,030"
"New cases: 40,340 (rectal cancer only)","​新发病例数：40,340（仅直肠癌）"
New chemotherapy regimens,新化疗方案
New drug regimens,新药方案
New fractionation schedules,新分割方案
Newer FOBTs: Nonrandomized Controlled Trial Evidence,新型FOBT：来自非随机对照试验的证据
No difference in OS was observed,两组OS无显著差异
No evidence of primary tumor,无原发肿瘤的证据
No regional lymph node metastases,无区域淋巴结转移
No regional lymph node metastasis,区域淋巴结无转移
No regional lymph node metastasis identified histologically,组织学上未见区域淋巴结转移
No virus confirmed,病毒不确定
Non-Small Cell Lung Cancer (PDQ®): Treatment,非小细胞肺癌（PDQ®）：治疗
None or tamoxifen,无，或他莫昔芬
Noninvasive breast cancer,非浸润性乳腺癌
Nonsteroidal anti-inflammatory drugs,非甾体类抗炎药
Nutrition in Cancer Care,癌症治疗中的营养治疗
OS was the primary outcome,试验的主要终点为OS
Observation after diagnostic biopsy,诊断性活检后观察
Occult NSCLC Treatment,隐匿性NSCLC的治疗
Occupational exposure to lung carcinogens,肺致癌原的职业暴露
Occupational exposures to lung carcinogens,肺致癌原的职业暴露
"Of these 11 patients, 9 survived",这11例患者中有9例存活
Okuda Staging System,Okuda分期系统
One Sv is equivalent to 200 mammograms,1 Sv的辐射剂量相当于进行200次乳腺X线摄影
Ongoing studies are evaluating these newer regimens,多项研究正在评估这些新化疗方案的有效性
Oral Complications of Chemotherapy and Head/Neck Radiation,化疗与头颈部放疗的口腔并发症
Orthotopic liver transplantation,原位肝移植
Other Treatment Approaches,其他治疗方法
Other environmental causes of lung cancer,导致肺癌的其他环境因素
Other prognostic factors include the following:,其他预后因素包括：
Other research on BSE is limited,其他关于BSE的研究十分有限
Other risk factors,​其他危险因素
Other risk factors and risk prediction models,其他危险因素和风险预测模型
Other systemic agents,其他全身用药
"Ovarian ablation, tamoxifen, and chemotherapy",卵巢去势、他莫昔芬和化疗
Overcoming nicotine dependence is often extremely difficult,戒除尼古丁依赖通常极为困难
Overview of Chemotherapy,治疗概述
Oxaliplatin with chemoradiation therapy,奥沙利铂联合放化疗
"PI3KCA, present in 2% of tumors",PI3KCA，见于2%的肿瘤
PIK3 catalytic protein alpha (PI3KCA),PIK3催化蛋白α（PI3KCA）
PRETEXT stage 1,PRETEXT 1期
PRETEXT stage 2,PRETEXT 2期
PRETEXT stage 3,PRETEXT 3期
PRETEXT stage 4,PRETEXT 4期
Palliative radiation therapy,姑息性放疗
"Palliative, endoscopic-placed stents to relieve obstruction",姑息性内镜下支架置入术缓解梗阻症状
Paraneoplastic cerebellar degeneration,副肿瘤性小脑变性
Pathologic Diagnosis of Breast Cancer,​乳腺癌的病理诊断
Pathological staging of NSCLC requires the following:,NSCLC的病理分期依据包括：
Patients receiving panitumumab experienced improved OS,帕尼单抗组的OS优于对照组
Patients were randomized in a 1:1 fashion,以1：1比例对患者随机分组
Patients with adenocarcinoma may benefit from pemetrexed,腺癌患者可能受益于培美曲塞
Perforation or obstruction of the bowel,是否存在肠穿孔或肠梗阻
Performance status (PS),身体状况评分（PS）
Personal history of breast cancer,既往乳腺癌病史
Pertuzumab plus trastuzumab,帕妥珠单抗联合曲妥珠单抗
Peutz-Jeghers syndrome: STK11 / LKB1 gene,​Peutz-Jeghers综合征：STK11/LKB1基因
Pharmacotherapy for smoking cessation,戒烟药物治疗
Polypectomy for select T1 cancers,对T1期肿瘤行选择性息肉切除术
Positioning of the woman is important,女性在检查中的体位亦十分重要
Positive axillary nodes,淋巴结转移阳性
Positivity Rate (%),阳性率（%）
Post-breast conservation surgery,保乳术后
Postmenopausal female hormone supplements,绝经后补充雌激素
"Postmenopausal, ER-negative or PR-negative",绝经后，ER阴性或PR阴性
"Postmenopausal, ER-positive or PR-positive",绝经后，ER阳性或PR阳性
Postoperative adjuvant chemotherapy,术后辅助化疗
Postsurgical Staging for Childhood Liver Cancer,儿童肝癌的术后分期
Posttreatment yp M classification,治疗后yp M分期
"Premenopausal, ER-negative or PR-negative",绝经前，ER阴性或PR阴性
"Premenopausal, ER-positive or PR-positive",绝经前，ER阳性或PR阳性
Preoperative Chemoradiation Therapy,术前同步放化疗
Preoperative Chemotherapy Alone,术前单纯化疗
Preoperative chemotherapy may also provide survival benefit,术前化疗也可能具有生存获益
Preoperative neoadjuvant chemotherapy,术前新辅助化疗
Presence of multifocal hepatic disease,是否存在多灶性肝病
Presence of pulmonary symptoms,有肺部症状
Presence or absence of distant metastases,是否存在远处转移
Presurgical Staging for Hepatoblastoma and Hepatocellular Carcinoma,肝母细胞瘤和肝细胞癌的术前分期
Preventing occupational exposure to lung carcinogens,预防肺癌致癌原的职业暴露
Prevention of Hepatitis B,乙肝的预防
Prior radiation therapy,既往放疗史
Prognostic and Predictive Factors,预后和预测因素
Progressive familial intrahepatic cholestasis,进行性家族性肝内胆汁淤积症
"Proliferative capacity of the tumor (e.g., Ki67)",肿瘤增殖能力（例如Ki67水平）
Prone patient positioning,患者俯卧位
Prophylactic cranial irradiation,预防性脑照射
Prophylactic cranial irradiation (PCI),预防性脑照射（PCI）
Prophylactic mastectomy: Benefits,预防性乳房切除术：获益
Prophylactic mastectomy: Harms,预防性乳房切除术：危害
Prophylactic oophorectomy or ovarian ablation: Benefits,预防性卵巢切除术或卵巢切除：获益
Prophylactic oophorectomy or ovarian ablation: Harms,预防性卵巢切除术或卵巢去势：危害
Pure fetal histology hepatoblastoma,单纯胎儿型肝母细胞瘤
Pylori infection eradication,幽门螺杆菌感染的根治
P—Main portal or portal bifurcation vein,P-主门静脉或门静脉分支静脉
RCT = randomized controlled trial,RCT=随机对照试验
RCTs have been consistent,RCT研究间结论一致
Radiation therapy (for palliation),放疗（缓解症状）
Radiation therapy alone,单独放疗
Radiation therapy and surgery,放疗与手术
Radiation therapy to the breast or chest,乳腺或胸部放疗
Radiofrequency Ablation in Dysplastic Barrett Esophagus,对有不典型增生的Barrett食管行射频消融术
Randomization: Cluster by birth date,随机分组：根据出生日期分组
Randomization: Individual volunteer (see NBSS-1),随机分组：个体随机分组（见前述NBSS-1）
Randomized controlled studies,随机对照研究
Randomized controlled trials,随机对照临床试验
Rationale for Screening,筛查的合理性
Rectal Cancer (PDQ®): Treatment,直肠癌（PDQ®）：治疗
Recurrent Esophageal Cancer,复发性食管癌
Recurrent Hepatocellular Carcinoma,肝细胞癌复发
Recurrent NSCLC Treatment,NSCLC复发的治疗
Recurrent Small Cell Lung Cancer Treatment,小细胞肺癌复发的治疗
Recurrent local-regional breast cancer,局部-区域复发性乳腺癌
Reducing or eliminating exposure to radon,减少或消除氡的暴露
Regional lymph node metastasis,有区域淋巴结转移
Regional lymph node(s) cannot be assessed,区域淋巴结无法评估
Regional treatment (radiation therapy),区域治疗（放疗）
Relative Mortality Reduction,相对死亡率降幅
"Resectable tumor invading pleura, pericardium, or diaphragm",可切除肿瘤侵及胸膜、心包或膈肌
Resected or resectable disease,已切除或可切除肿瘤
Resection of isolated pulmonary or ovarian metastases,孤立性肺转移灶或卵巢转移灶切除术
Results are expected in 2016,预期将在2016年公布结果
Results have been inconsistent,研究结果并不一致
Results of case-control studies have been mixed,一些病例对照研究的结果并不一致
Results were summarized in two systematic reviews,两篇系统性综述总结了这些试验的结果
Reviewers and Updates,​审核人与更新
Risk Factors for Breast Cancer,​乳腺癌的危险因素
Risk in Next 10 Years,未来10年内的风险
Risk increases with age,风险随年龄增长而增加
Rofecoxib 25 mg/qd,罗非考昔25 mg/qd
Rofecoxib <25 mg/qd; rofecoxib >25 mg/qd,罗非考昔＜25 mg/qd；罗非考昔＞25 mg/qd
Routine blood counts and serum chemistries,血常规与生化
Ruvalcaba–Myhre–Smith syndrome: PTEN gene,​Ruvalcaba-Myher-Smith综合征：PTEN基因
"Sample size: 21,088 study and 21,195 control","样本量：试验组和对照组分别为21,088例和21,195例受试者"
"Sample size: 23,226 study and 21,904 control","样本量：试验组和对照组分别有23,226例和21,904例受试者"
Screening With Mammography,乳腺X线摄影筛查
Screening by chest x-ray and/or sputum cytology,胸部X线检查和（或）痰细胞学
Screening by low-dose helical computed tomography,低剂量螺旋CT筛查
Secondhand tobacco smoke,二手烟
Selective estrogen receptor modulators (SERMs),选择性雌激素受体调节剂（SERM）
Selective estrogen receptor modulators (SERMs): Benefits,选择性雌激素受体调节剂（SERM）：获益
Selective estrogen receptor modulators (SERMs): Harms,选择性雌激素受体调节剂（SERM）：危害
Sentinel node biopsy,前哨淋巴结活检
Sequential or concurrent chemotherapy and radiation therapy,序贯或同步放化疗
Seventeen studies met inclusion criteria,共有17项研究满足入选标准
Seventh Edition T/M,第7版T/M
Several CAD systems are in use,目前已有部分CAD系统正在应用之中
Several studies have tested different chemotherapy regimens,另几项研究比较了不同化疗方案的效果
Sexuality and Reproductive Issues,性功能与生殖系统问题
Shorter hypofractionation schemes achieve comparable results,短暂低剂量分次模式亦可获得类似疗效
Signet ring adenocarcinoma,印戒细胞腺癌
Signet-ring cell carcinoma,印戒细胞癌
Similar benefit may be achieved with erlotinib,厄洛替尼治疗后可达到类似获益
"Single-read first three rounds, then double-read",前三次筛查仅单次阅片，之后为双重阅片
Sites of tumor involvement,肿瘤侵犯部位
Sixth Edition T/M Descriptor (cm),第6版T/M定义（cm）
"Sixty-five trials (13,601 patients) were identified","共检索到65项临床试验（13,601例患者）"
Size of the primary tumor,原发肿瘤的大小
Skills training/problem solving (cessation/abstinence techniques),技能培训/问题解决（戒烟/戒断方法）
Slightly more than 20% had received chemotherapy,超过20%的患者已接受化疗
Small Cell Lung Cancer (PDQ®): Treatment,小细胞肺癌（PDQ®）：治疗
Small cell undifferentiated hepatoblastoma,小细胞未分化型肝母细胞瘤
Smoke-free workplace legislation,无烟工作环境立法
Smoking avoidance and cessation,回避吸烟与戒烟
Smoking cessation guidelines,戒烟指南
Smoking in Cancer Care,吸烟与癌症治疗
Smoking-related lung carcinogenesis is a multistep process,吸烟相关肺癌变是一个多步骤过程
Solid adenocarcinoma with mucin,实性腺癌伴黏液
Solitary tumor without vascular invasion,实体肿瘤，无血管浸润
Special considerations for surgical resection,手术切除的特殊考虑因素
Specificity and false-positive rate,特异性和假阳性率
Specificity declined from 97.8% to 96%,特异性从97.8%降低到96%
Specificity was 86% and PPV was 23%,特异性为86%，PPV为23%
Spindle cell carcinoma,梭形细胞癌
"Sporadic adenoma prevention trial (N = 2,035)","散发性腺瘤预防试验（N=2,035）"
Squamous Cell Cancer,鳞状细胞癌
Squamous Cell Carcinoma,食管鳞状细胞癌
Squamous cell carcinoma,鳞状细胞癌
Squamous cell carcinoma (25% of lung cancers),鳞状细胞癌（25%的肺癌）
Stage ( TNM Staging Criteria ),分期（TNM分期标准）
Stage 0 Colon Cancer,0期结肠癌
Stage 0 Colon Cancer Treatment,0期结肠癌的治疗
Stage 0 Esophageal Cancer,0期食管癌
Stage 0 Gastric Cancer,0期胃癌
Stage 0 NSCLC,0期NSCLC
Stage 0 NSCLC Treatment,0期NSCLC的治疗
Stage 0 Rectal Cancer,0期直肠癌
Stage 0 colon cancer,0期结肠癌
Stage I Colon Cancer,I期结肠癌
Stage I Colon Cancer Treatment,I期结肠癌的治疗
Stage I Esophageal Cancer,I期食管癌
Stage I Gastric Cancer,I期胃癌
Stage I Rectal Cancer,I期直肠癌
Stage II Colon Cancer,II期结肠癌
Stage II Colon Cancer Treatment,II期结肠癌的治疗
Stage II Esophageal Cancer,II期食管癌
Stage II Gastric Cancer,II期胃癌
Stage II Rectal Cancer,II期直肠癌
Stage III Colon Cancer,III期结肠癌
Stage III Colon Cancer Treatment,III期结肠癌的治疗
Stage III Esophageal Cancer,III期食管癌
Stage III Gastric Cancer,III期胃癌
Stage III Rectal Cancer,III期直肠癌
Stage III colon cancer,III期结肠癌
Stage IIIA NSCLC,IIIA期NSCLC
Stage IIIA NSCLC Treatment,IIIA期NSCLC的治疗
Stage IIIB NSCLC,IIIB期NSCLC
Stage IIIB NSCLC Treatment,IIIB期NSCLC的治疗
Stage IV (distant metastases),IV期（远处转移）
Stage IV Esophageal Cancer,IV期食管癌
Stage IV NSCLC,IV期NSCLC
Stage IV NSCLC Treatment,IV期NSCLC的治疗
Stage IV and Recurrent Colon Cancer Treatment,IV期结肠癌与复发性结肠癌的治疗
Stage IV and Recurrent Gastric Cancer,IV期胃癌与复发胃癌
Stage IV and Recurrent Rectal Cancer,IV期与复发性直肠癌
Stage IV and metastatic disease,IV期与转移性乳腺癌
Stage IV colon cancer,IV期结肠癌
"Stage IV, Recurrent, and Metastatic Breast Cancer",IV期、复发性与转移性乳腺癌
Stage Information for Adult Primary Liver Cancer,成人原发性肝癌的分期
Stage Information for Breast Cancer,乳腺癌分期
Stage Information for Colon Cancer,结肠癌的分期信息
Stage Information for Esophageal Cancer,食管癌的分期信息
Stage Information for Gastric Cancer,胃癌分期信息
Stage Information for NSCLC,NSCLC的分期
Stage Information for Rectal Cancer,直肠癌的分期信息
Stage Information for Small Cell Lung Cancer,分期评估
Stages I and II,I期与II期肿瘤
Stages IA and IB NSCLC,IA与IB期NSCLC
Stages IA and IB NSCLC Treatment,IA与IB期NSCLC的治疗
Stages IIA and IIB NSCLC,IIA与IIB期NSCLC
Stages IIA and IIB NSCLC Treatment,IIA与IIB期NSCLC的治疗
Stages III and IV are usually fatal,III期与IV期肝细胞癌通常致死
Standard Treatment Options,标准治疗方案
Standard Treatment Options for Occult NSCLC,隐匿性NSCLC的标准治疗选择
Standard Treatment Options for Recurrent NSCLC,NSCLC复发的标准治疗选择
Standard Treatment Options for Stage 0 NSCLC,0期NSCLC的标准治疗选择
Standard Treatment Options for Stage IIIB NSCLC,IIIB期NSCLC的标准治疗选择
Standard Treatment Options for Stage IV NSCLC,IV期NSCLC的标准治疗选择
Standard staging procedures include the following:,标准分期程序包括：
Stereotactic radiation surgery (for highly selected patients),立体定向放疗（适用于经详细选择的患者）
Stomach (Gastric) Cancer (PDQ®): Prevention,胃癌（PDQ®）：预防
Stomach (Gastric) Cancer (PDQ®): Screening,胃癌（PDQ®）：筛查​
Stomach (Gastric) Cancer Screening,胃癌筛查
Stool DNA Mutation Tests,便DNA突变检测
"Stroke RR, 1.06 (0.83–1.36)",卒中RR，1.06（0.83-1.36）
Studies in progress,正在进展中的研究
Study Design : Ecologic and descriptive studies,研究设计：生态学与描述性研究
Study Design : Randomized controlled trials,研究设计：随机对照试验
Study Design : Two RCTs,​研究设计： 两项RCT
"Study Design : Two RCTs, cohort studies",​研究设计：两项RCT及队列研究
Study Design: Case-control and cohort studies,研究设计：病例对照与队列研究
"Study Design: Case-control, cohort, and observational studies",研究设计：观察、病例对照与队列研究
Study Design: Cohort and RCTs,研究设计：队列与RCT
Study Design: Cohort and case-control studies,研究设计：队列研究与病例对照研究
Study Design: Cohort studies,研究设计：队列研究
Study Design: Cohort studies and meta-analysis,研究设计：队列研究与荟萃分析
Study Design: Convenience sample,研究设计：便利样本
Study Design: Evidence from RCTs,研究设计：来自RCT的证据
Study Design: Evidence from retrospective cohort studies,研究设计：来自回顾性队列研究的证据
Study Design: Evidence obtained from large databases,研究设计：来自大型数据库的证据
Study Design: Extended follow-up of four RCTs,研究设计：4项RCT的延期随访
Study Design: Large cohort studies,研究设计：大型队列研究
Study Design: Meta-analyses of RCTs,研究设计：RCT荟萃分析
Study Design: Observational study,研究设计：观察性研究
"Study Design: Observational, case-control, and cohort studies",研究设计：观察、病例对照与队列研究
Study Design: One RCT,研究设计：一项RCT
Study Design: One randomized controlled trial,研究设计：一项随机对照试验
Study Design: One-hundred six observational studies,研究设计： 106项观察性研究
Study Design: Prospective observational and case-control studies,研究设计：前瞻性观察研究和病例对照研究
Study Design: RCT and cohort studies,研究设计：RCT与队列研究
Study Design: RCTs,研究设计：RCT
Study Design: Randomized controlled trials,研究设计：随机对照临床试验
Study design : Descriptive population-based,研究设计： 基于人群的描述性研究
Such results have not been observed,然而这样的结果并未出现
Summary of RCTs,RCT总结
Superior sulcus tumors,上沟瘤
Superior vena cava syndrome,上腔静脉综合征
Surgery alone (for selected patients),单独手术（适用于部分患者）
Surgery and chemotherapy,手术与化疗
Surgery and radiation therapy,手术与放疗
Surgery followed by chemotherapy or chemoradiation therapy,手术加化疗或放化疗
Surgery followed by chemotherapy or chemoradiotherapy,手术后化疗或放化疗
Surgical resection for metastatic disease,转移灶的手术切除
Surgical resection of locally recurrent cancer,手术切除局部复发性结肠癌
Surgical resection of the primary tumor,原发肿瘤手术切除
Survival was 100% with no chemotherapy given,无化疗的情况下生存率达100%
Sweats and Hot Flashes,出汗与潮热
Systemic chemotherapy (see below),全身化疗（详见下文）
"Systemic treatments (chemotherapy, immunotherapy, and targeted agents)",全身治疗（化疗、免疫治疗与靶向药物）
T0 = No evidence of primary tumor,T0=无原发性肿瘤证据
T1 = Tumor invades submucosa,T1 = 肿瘤侵犯粘膜下层
T1 includes T1mi,T1包括T1mi
T2 = Tumor invades muscularis propria,T2 = 肿瘤侵犯固有肌层
T4 (pleural effusion),T4（胸腔积液）
T4 (same lobe nodules),T4（同一肺叶结节）
TX = Primary tumor cannot be assessed,TX = 原发肿瘤无法评估
Table 1. Definitions of TNM Stage 0,表1.TNM 0期的定义
Table 1. Primary Tumor,表1.原发肿瘤
Table 1. Primary Tumor (T),表1. 原发肿瘤（T）
Table 1. Risk of Breast Cancer Diagnosis,表1. 乳腺癌的诊断风险
Table 10. Definitions of TNM Stage IV,表10. TNM IV期的定义
Table 11. Standard Treatment Options for NSCLC,表11. NSCLC的标准治疗选择
Table 2. Definitions of TNM Occult Carcinoma,表2. TNM隐匿性癌的分期定义
Table 2. Definitions of TNM Stage I,表2.TNM I期的定义
Table 2. Regional Lymph Nodes (N),表2. 区域淋巴结（N）
Table 3. Definitions of TNM Stage 0,表3. TNM 0期的定义
Table 3. Definitions of TNM Stage II,表3.TNM II期的定义
Table 3. Distant Metastasis,表3. 远处转移
Table 3. Distant Metastasis (M),表3. 远处转移（M）
Table 3. Likely Etiology of Hepatocellular Carcinoma,表3. 肝细胞癌病因
Table 4. Anatomic Stage/Prognostic Groups,表 4. 解剖分期/预后分组
Table 4. Definitions of TNM Stage IA,表4. TNM IA期的定义
Table 4. Definitions of TNM Stage III,表4.TNM III期的定义
Table 5. Definitions of TNM Stage IB,表5. TNM IB期的定义
Table 5. Definitions of TNM Stage IV,表5.TNM IV期的定义
Table 6. Definitions of TNM Stage IIA,表6. TNM IIA期的定义
Table 7. Definitions of TNM Stage IIB,表7. TNM IIB期的定义
Table 8. Definitions of TNM Stage IIIA,表8. TNM IIIA期的定义
Table 9. Definitions of TNM Stage IIIB,表9. TNM IIIB期的定义
Tamoxifen (under clinical evaluation),他莫昔芬（在临床评估阶段）
Tamoxifen and chemotherapy,他莫昔芬和化疗
Tamoxifen for estrogen receptor–positive patients,雌激素受体阳性患者可接受他莫昔芬治疗
Tamoxifen toxic effects,他莫昔芬的毒性作用
The CI was near 1.0,CI接近1.0
"The PPVs were 14% and 73%, respectively",PPV分别为14%和73%
The Role of Oxaliplatin for Localized Disease,奥沙利铂对局限病变的作用
The Swedish meta-analysis resolved these questions appropriately,瑞典荟萃分析适当地解决了这些问题
The analysis did not include fiber supplements,该分析不包括补充纤维素
The biology of carcinogenesis,致癌的生物学机制
The chemotherapy was well tolerated,患儿对新辅助化疗的耐受性较好
The comparison group was not actively followed,对照组无积极随访
The epidemiology of these types varies markedly,不同类型食管恶性肿瘤的流行病学特征有显著差异
The etiology of HCC is likely multifactorial,HCC可能由多因素引起
The most common histologies include the following:,最常见的组织学类型包括下列：
The optimal surgical procedure is controversial,目前对于优先选用何种手术方式仍有争议
The overall 5-year survival rate is 64%,结直肠癌的5年生存率为64%
The patient's performance status (PS),患者体能状况（PS）
The presence or absence of distant metastases,是否有远处转移
The presence or absence of nodal involvement,是否累及淋巴结
The primary endpoint was CRC-specific mortality,主要终点为CRC相关死亡率
The primary endpoint was PFS,主要终点为PFS
The primary endpoint was lung cancer incidence,主要终点为肺癌发病率
The results varied in different publications,不同文献报道的结果不同
The risk declines with smoking cessation,戒烟后食管鳞癌发生风险降低
The stage of the disease,肿瘤分期
The study reported the following,研究结果如下
The use of high-energy radiation machines,使用高能量的放疗仪器
The use of multiple pelvic fields,使用多盆腔野放疗
The value of PORT has been assessed,有研究评估了术后（辅助）放疗（PORT）的意义
There are positive lymph nodes,淋巴结阳性
There was no effect on all-cause mortality,但筛查不影响全因死亡率
These groups include the following:,相关遗传性疾病包括：
These studies have yielded conflicting results,这些研究结果并不一致
This is a group of rare tumors,这是一组罕见肿瘤
Time-to-treatment progression (TTP) was the primary endpoint,选择疾病进展时间（TTP）为主要终点
Timing of Primary and Adjuvant Therapy,主要治疗和辅助治疗的时机
Timing of surgery,手术时机
Tis = Carcinoma in situ,Tis=原位癌
To assess the efficacy of initial therapy,评估初步治疗的效果
To be determined,尚待研究
To detect new or metachronous malignancies,检测是否有新发肿瘤或异时性癌
"Tobacco, Alcohol, and Dietary Factors",吸烟，饮酒与饮食因素
Topotecan is standard chemotherapy for recurrent SCLC,拓扑替康是SCLC复发后的标准化疗
Total mastectomy with or without tamoxifen,乳房单纯切除术，加用或不加用他莫昔芬
"Tracheal, esophageal, or bronchial compression",气管、食管或支气管压迫
Transitional liver cell tumor,过渡型肝细胞肿瘤
Trastuzumab (under clinical evaluation),曲妥珠单抗（在临床评估阶段）
Treatment Option Overview,治疗方案概述
Treatment Option Overview for Colon Cancer,结肠癌治疗选择概述
Treatment Option Overview for NSCLC,NSCLC的治疗方法概述
Treatment Options Under Clinical Evaluation,处于临床评估阶段的治疗方法
Treatment Options for Male Breast Cancer,男性乳腺癌的治疗选择
Treatment Options for Patients With DCIS,DCIS患者的治疗方案
Treatment Options for Patients With LCIS,LCIS患者的治疗方案
Treatment Options for Postsurgically Staged Stage IV,术后分期为IV期患者的治疗选择
Treatment Options for Stage III,III期肝母细胞瘤的治疗选择
Treatment Options for Stage IV,IV期肝母细胞瘤的治疗选择
Treatment Options for Stages I and II,I期与II期肝母细胞瘤的治疗选择
Treatment by stage--legacy,依据分期的治疗--legacy
Treatment of Hepatoblastoma,肝母细胞瘤的治疗
Treatment of Hepatocellular Carcinoma,肝细胞癌的治疗
Treatment of Infantile Choriocarcinoma of the Liver,婴儿肝绒毛膜癌的治疗
Treatment of Liver Metastasis,肝转移治疗
Treatment of Recurrent Childhood Liver Cancer,儿童肝癌复发的治疗
Treatment of brain metastases,脑转移的治疗
Treatment of second primary tumor,第二原发肿瘤的治疗
Treatment of these cancers would constitute overtreatment,对这些肿瘤进行治疗将会导致过度治疗
Treatment option overview--legacy,治疗选择概述--后遗效应
Treatment options by cell type,不同细胞类型的治疗选择
Treatment options by stage,根据分期的治疗选择
Treatment options for older patients,老年患者的治疗选择
Treatment options for recurrent cancer,癌症复发的治疗方法
Triple-Negative Breast Cancer,三阴性乳腺癌
"Trisomy 18, other trisomies",18三体综合征或其他三体综合征
Tumor >50 mm in greatest dimension,肿瘤最大径>50 mm
Tumor invades adjacent structures,肿瘤侵及邻近器官
Tumor invades adventitia,肿瘤侵及食管纤维膜
Tumor invades lamina propria or muscularis mucosae,肿瘤侵及固有层或粘膜肌层
Tumor invades muscularis propria,肿瘤侵及固有肌层
Tumor invades serosa (visceral peritoneum),肿瘤侵犯浆膜（脏层腹膜）
Tumor invades submucosa,肿瘤侵及粘膜下层
Tumor marker–related factors,肿瘤标志物相关因素
Tumor size and location,肿瘤大小与部位
Tumor ≤1 mm in greatest dimension,肿瘤最大径≤1 mm
Tumor ≤20 mm in greatest dimension,肿瘤最大径≤20 mm
Tumors that invade the chest wall,侵及胸壁的肿瘤
Tumors with an extensive intraductal component,​伴有大量导管内癌成分
Turcot syndrome: APC gene; MMR genes,​Turcot综合征：APC基因，MMR基因
Two included sputum cytology as well,两项研究也分析了痰细胞学
Undifferentiated Embryonal Sarcoma of the Liver,肝脏未分化胚胎性肉瘤
Use of statins,他汀类药物
Validity of dietary questionnaires used,选用的饮食调查问卷效度
Veterans Administration Lung Study Group (VALG),退伍军人管理局肺癌研究组（VALG）分期系统
Vinorelbine and epirubicin,长春瑞滨联合表柔比星
Virtual Colonoscopy (Computed Tomographic [CT] Colonography),虚拟结肠镜（计算机断层[CT]结肠成像）
Viruses Associated With Hepatitis and/or Hepatocellular Cancer,与肝炎和（或）肝细胞癌相关的病毒
Vitamin E (Tocopherol),维生素E（生育酚）
Vitamin E supplementation,补充维生素E
Vocal cord paralysis,声带麻痹
V—Vena cava or all three hepatic veins,V-下腔静脉或所有三支肝静脉
WHO/IASLC Histologic Classification of NSCLC,WHO/IASLC的NSCLC组织学分类
Well-differentiated fetal adenocarcinoma,分化良好的胎儿型腺癌
Who is at Risk,哪些人是结直肠癌的危险人群
Wide surgical resection and anastomosis,广泛切除联合肠吻合术
Women who have received thoracic radiation,既往接受过胸部放疗的女性
Women with limited life expectancy,预期寿命有限的女性
adult primary liver cancer,成人原发性肝癌
and offers palliation of symptomatic metastatic disease,且可能缓解肿瘤转移产生的症状
"be discussed at a meeting,",​开会讨论，
childhood hepatocellular carcinoma,儿童肝细胞癌
childhood liver cancer,儿童肝癌
ductal breast carcinoma in situ,导管原位癌
extensive stage small cell lung cancer,广泛期小细胞肺癌
iFOBT detects >60% and ≤90% of CRCs,iFOBT对CRC的检出率＞60%且≤90%
inflammatory breast cancer,炎性乳腺癌
limited stage small cell lung cancer,局限期小细胞肺癌
lobular breast carcinoma in situ,小叶原位癌
male breast cancer,男性乳腺癌
non-small cell lung cancer,非小细胞肺癌
occult lung cancer,隐匿性肺癌
occult non-small cell lung cancer,隐匿性非小细胞肺癌
recurrent breast cancer,复发性乳腺癌
recurrent childhood liver cancer,儿童肝癌复发
recurrent colon cancer,复发性结肠癌
recurrent esophageal cancer,复发性食管癌
recurrent non-small cell lung cancer,非小细胞肺癌复发
recurrent rectal cancer,复发性直肠癌
recurrent small cell lung cancer,小细胞肺癌复发
small cell lung cancer,小细胞肺癌
stage 0 NSCLC,0期NSCLC
stage 0 colon cancer,0期结肠癌
stage 0 esophageal cancer,0期食管癌
stage 0 gastric cancer,0期胃癌
stage 0 non-small cell lung cancer,0期非小细胞肺癌
stage 0 rectal cancer,0期直肠癌
stage I breast cancer,I期乳腺癌
stage I colon cancer,I期结肠癌
stage I esophageal cancer,I期食管癌
stage I gastric cancer,I期胃癌
stage I non-small cell lung cancer,I期非小细胞肺癌
stage I rectal cancer,I期直肠癌
stage IA NSCLC,IA期NSCLC
stage II breast cancer,II期乳腺癌
stage II colon cancer,II期结肠癌
stage II esophageal cancer,II期食管癌
stage II gastric cancer,II期胃癌
stage II non-small cell lung cancer,II期非小细胞肺癌
stage II rectal cancer,II期直肠癌
stage III colon cancer,III期结肠癌
stage III esophageal cancer,III期食管癌
stage III gastric cancer,III期胃癌
stage III rectal cancer,III期直肠癌
stage IIIA NSCLC,IIIA期NSCLC
stage IIIA breast cancer,IIIA期乳腺癌
stage IIIA non-small cell lung cancer,IIIA期非小细胞肺癌
stage IIIB NSCLC,IIIB期NSCLC
stage IIIB breast cancer,IIIB期乳腺癌
stage IIIB non-small cell lung cancer,IIIB期非小细胞肺癌
stage IIIC breast cancer,IIIC期乳腺癌
stage IV NSCLC,IV期NSCLC
stage IV breast cancer,IV期乳腺癌
stage IV colon cancer,IV期结肠癌
stage IV disease,IV期肿瘤
stage IV esophageal cancer,IV期食管癌
stage IV gastric cancer,IV期胃癌
stage IV non-small cell lung cancer,IV期非小细胞肺癌
stage IV rectal cancer,IV期直肠癌
stages IIA NSCLC,IIA期NSCLC
triple-negative breast cancer,三阴性乳腺癌
–M0 includes M0(i+),–M0包括M0(i+)
